TRUCHECK INTELLI (early cancer detection of up to 70 solid tumours)

About 4.4 million new cancers are detected every year in Europe as well as about 2 million cancer related deaths. Unfortunately, some cancers are detected at advanced stages which necessitate more intensive and expensive treatments which have greater risk of side effects. Detection of cancers at early / local stages is vital for successful treatments, lower treatment costs, lower toxicities and improved survival.

Trucheck™ is the culmination of years of collaborative international research and innovation and has been developed, tested and validated on > 40.000 individuals.

• Trucheck™ detects circulating tumour cells (CTCs) and clusters of these CTCs which are released by malignant tumours, but not from non-cancerous (normal / benign tumour / inflammatory) tissue. Hence CTCs are ubiquitously seen in blood of cancer patients but absent in blood of healthy individuals.

• Trucheck™ intelli can distinguish ~70 types of solid tumours which account for ~81% of all cancer cases and ~84% of all cancer related deaths in Europe.

• Trucheck™ has a 92.1% sensitivity in detection of cancers across all stages and types. Further Trucheck™ intelli has a 93.1% accuracy in determining the tissue or organ of origin in positive cases.

• Trucheck™ displays a specificity of 99.9% (versus healthy individuals). Trucheck™ detects cancers irrespective of the extent of the disease, thus even early-stage cancers are reliably observed.

Please see further information in the TruCheck brochure.

Please note that we no longer offer Trucheck, as our work now focuses solely on supporting patients after a cancer diagnosis.